RxDoctor Payments Data

Madiha Salim, MD

Internal Medicine · Walled Lake, MINPI 1760845895

Payments from drug & device makers

$2,933in general payments, 2019–2025

Across 149 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$558
  • AstraZeneca$557
  • Lilly USA, LLC$223
  • Pfizer$216
  • AbbVie$206
  • GSK$186
  • plus $986 from 18 others

What the payments were for

  • Food & beverage$2,88398%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,933 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$57,350
Medicare patients
158
Services billed
2,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$52,044
JardianceEmpagliflozin43$48,747
FarxigaDapagliflozin Propanediol40$42,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$35,036
MounjaroTirzepatide20$26,125
TrulicityDulaglutide11$22,777
OzempicSemaglutide22$22,080
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$14,118
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$8,095
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,331
Albuterol Sulfate HfaAlbuterol Sulfate111$3,643
Atorvastatin Calcium257$2,579
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,078
Omeprazole96$1,863
Levothyroxine Sodium136$1,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$557$56,41652 claims
PfizerEliquis$216$52,04448 claims
Lilly USA, LLCMounjaro, Trulicity$223$48,90231 claims
Boehringer IngelheimJardiance$136$48,74743 claims
GSKTrelegy Ellipta$186$35,03625 claims
Novo NordiskOzempic$558$22,08022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Walled Lake

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →